The Effects of helicobacter pylori eradication therapy on clinical symptoms and quality of life of patients with functional dyspepsia who were positive for helicobacter pylori and associated with mild to moderate anxiety or depression

Effect of eradication of Helicobacter pylori on clinical symptoms and quality of life in patients with functional dyspepsia who were positive for Helicobacter pylori and mild to moderate anxiety or depression

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900024264

Enrollment

Unknown

Registered

2019-07-03

Start date

2019-07-04

Completion date

Unknown

Last updated

2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

functional dyspepsia

Interventions

group A:Helicobacter pylori eradication

group B:Anti-anxiety and depression treatment

group C:Helicobacter pylori eradication therapy combined with anti-anxiety and depression treatment

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Outpatients who are treated for dyspepsia symptoms meet the Rome-IV FD diagnostic criteria, which has symptoms of early satiety, postprandial fullness, upper abdominal pain, upper abdomen burning sensation for at least 6 months, the above symptoms persisted for nearly 3 months; (2) the 13C-urea breath test was positive; (3) the Hamilton Anxiety Scale (HAMA) score was 14-29 points; or the Hamilton Depression Scale 24 (HMDA) score was 20-35 Minute. (4) aged between 18 and 70 years; (5) signing informed consent; (6) not participating in other research projects in the past three months.

Exclusion criteria

Exclusion criteria: (1) There are serious systemic diseases, including malignant tumors, advanced chronic kidney disease, diabetes, cirrhosis, and blood system diseases; (2) gastroscopic findings of organic digestive tract lesions, including peptic ulcer, erosive gastritis, atrophic Gastritis, erosive esophagitis, Barrett's esophagitis, digestive tract tumors; (3) abdominal B-ultrasound, CT or laboratory examination found liver, gallbladder, pancreatic organic diseases, including hepatitis, cholecystitis, pancreatitis; (4) history of abdominal surgery; (5) history of allergies to test drugs; (6) history of mental illness, long-term or intermittent use of antipsychotic drugs; (7) anxiety and depressive episodes secondary to other neuropsychiatric or physical diseases; (8) have persistent, major mental stimulation or long-term stress; (9) have a birth plan, or are in pregnancy and lactation; (10) long-term use of aspirin, anticoagulants, NSAIDS and antibiotics; (11) combined intestines Irritable syndrome; (12) unwilling to sign informed consent and refuse to participate in the investigation.

Design outcomes

Primary

Measure	Time frame
Gastrointestinal symptoms;Hamilton Anxiety Scale 14 items;Hamilton Depression Scale 24 items;Quality of Life Scale (SF-36);	—

Countries

China

Contacts

Public ContactGu Sai

The First Affiliated Hospital of Chongqing Medical University

1601792466@qq.com+86 13018339696

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026